1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals

BackgroundHealth utilities are measures of quality of life, which are used to obtain quality-adjusted life years in pharmacoeconomic evaluations. A short-term utility improvement has been recently reported after hepatitis C viral clearance, although scarce data exists regarding the long-term variati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A1-A1
Hauptverfasser: Juanbeltz, R, Goñi-Esarte, S, Martínez-Baz, I, San Miguel, R, Zozaya, JM, Rivero, M, Herrero, I, Larrayoz, B, Sarobe, M, Castilla, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A1
container_issue Suppl 1
container_start_page A1
container_title European journal of hospital pharmacy. Science and practice
container_volume 26
creator Juanbeltz, R
Goñi-Esarte, S
Martínez-Baz, I
San Miguel, R
Zozaya, JM
Rivero, M
Herrero, I
Larrayoz, B
Sarobe, M
Castilla, J
description BackgroundHealth utilities are measures of quality of life, which are used to obtain quality-adjusted life years in pharmacoeconomic evaluations. A short-term utility improvement has been recently reported after hepatitis C viral clearance, although scarce data exists regarding the long-term variation of these parameters.PurposeTo assess the change in health utility values for patients cured of hepatitis C virus infection, one year after successful treatment with direct-acting antivirals, and the variables associated to that change.Material and methodsObservational, prospective study included cured patients with oral direct-acting antivirals between May 2016 and April 2017. The EQ-5D-5L questionnaire was used to obtain utilities, previous therapy and one year after its end (post48). Differences in the utility medians were compared using the Wilcoxon test. The percentage of disutility reduction was obtained as (post48 – baseline)/(1-baseline)×100. Multivariable linear regression analysis was carried out, adjusting by sex, age, HIV co-infection, baseline limitation of mobility, anxiety-depression and degree of liver fibrosis before treatment. Outcome variable was the difference post48 – baseline utility value.ResultsOne hundred and ninety-nine patients were enrolled, 65% male. Cirrhosis was present in 29% of the patients and HIV co-infection in 32%. Globally, median health utilities increased from 0.857 at baseline to 0.932 at post-48 (+0.075, p
doi_str_mv 10.1136/ejhpharm-2019-eahpconf.1
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2190010866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190010866</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1221-e806a9d3e9774ce68e7bede4f8d377ba22e7c92eb1d47dd2a7ba7de431f16c53</originalsourceid><addsrcrecordid>eNo9kM1KAzEUhQdRsGjfIeA6NT_TZLKUom2h4MLuQyZzx0mZzoxJRulCcOOL-iSm1Lq6h3MP53K_LEOUzCjl4h52zdAYv8eMUIXBNIPtu3pGL7IJI7nESon88l_PxXU2DcGVZM55oXKuJtknXb8sMSH05-t7BaaNDRqja110EJDrkG183zmLGhhMTG5AC3RU0MWA-g7QAYxHpo7gURithRDqsUXRg4n7FEIfLlVWzoON2NjouldkuujenTdtuM2u6jRg-jdvsu3T43axwpvn5XrxsMElZYxiKIgwquKgpMwtiAJkCRXkdVFxKUvDGEirGJS0ymVVMZM8mfac1lTYOb_J7k61g-_fRghR7_rRd-miZlSl50khRErxU6rc7_Tg3d74g6ZEH0nrM2l9JK3PpDXlvwCzejU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190010866</pqid></control><display><type>article</type><title>1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Juanbeltz, R ; Goñi-Esarte, S ; Martínez-Baz, I ; San Miguel, R ; Zozaya, JM ; Rivero, M ; Herrero, I ; Larrayoz, B ; Sarobe, M ; Castilla, J</creator><creatorcontrib>Juanbeltz, R ; Goñi-Esarte, S ; Martínez-Baz, I ; San Miguel, R ; Zozaya, JM ; Rivero, M ; Herrero, I ; Larrayoz, B ; Sarobe, M ; Castilla, J</creatorcontrib><description>BackgroundHealth utilities are measures of quality of life, which are used to obtain quality-adjusted life years in pharmacoeconomic evaluations. A short-term utility improvement has been recently reported after hepatitis C viral clearance, although scarce data exists regarding the long-term variation of these parameters.PurposeTo assess the change in health utility values for patients cured of hepatitis C virus infection, one year after successful treatment with direct-acting antivirals, and the variables associated to that change.Material and methodsObservational, prospective study included cured patients with oral direct-acting antivirals between May 2016 and April 2017. The EQ-5D-5L questionnaire was used to obtain utilities, previous therapy and one year after its end (post48). Differences in the utility medians were compared using the Wilcoxon test. The percentage of disutility reduction was obtained as (post48 – baseline)/(1-baseline)×100. Multivariable linear regression analysis was carried out, adjusting by sex, age, HIV co-infection, baseline limitation of mobility, anxiety-depression and degree of liver fibrosis before treatment. Outcome variable was the difference post48 – baseline utility value.ResultsOne hundred and ninety-nine patients were enrolled, 65% male. Cirrhosis was present in 29% of the patients and HIV co-infection in 32%. Globally, median health utilities increased from 0.857 at baseline to 0.932 at post-48 (+0.075, p&lt;0.001). In HIV co-infected patients, utilities increased from 0.871 to 0.932 at post 48 (+0.061, p=0.001) and in cirrhotic patients from 0.809 to 0.890 (+0.081, p&lt;0.001). This improvement supposed a whole reduction in disutility of 52%: 47% in HIV co-infected and 42% in cirrhotic patients. In multivariate analysis, moderate-advanced fibrosis (F2–F3) and cirrhosis were associated with higher utility improvement than those with lower fibrosis degree (β=0.06; 95% CI, 0.001 to 0.12 and β=0.07; 95% CI, 0.003 to 0.13, respectively).ConclusionA long-term improvement in health utilities occurs in chronic hepatitis C patients successfully treated with direct-acting antivirals, even in HCV/HIV co-infected. This benefit is especially evident in patients with advanced fibrosis. The availability of utility values obtained directly from treated patients contributes to future economic evaluations of these new drugs.References and/or acknowledgementsEIPT-VHC project funded by the Spanish Ministry of Health and Carlos III Institute of Health.Conflict of interestCorporate-sponsored research or other substantive relationships:Regina Juanbeltz has received funding from the Carlos III Institute of Health with the European Regional Development Fund (CM17/00095).</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-eahpconf.1</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Hepatitis ; Hepatitis C ; Infections ; Liver cirrhosis</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A1-A1</ispartof><rights>2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Juanbeltz, R</creatorcontrib><creatorcontrib>Goñi-Esarte, S</creatorcontrib><creatorcontrib>Martínez-Baz, I</creatorcontrib><creatorcontrib>San Miguel, R</creatorcontrib><creatorcontrib>Zozaya, JM</creatorcontrib><creatorcontrib>Rivero, M</creatorcontrib><creatorcontrib>Herrero, I</creatorcontrib><creatorcontrib>Larrayoz, B</creatorcontrib><creatorcontrib>Sarobe, M</creatorcontrib><creatorcontrib>Castilla, J</creatorcontrib><title>1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundHealth utilities are measures of quality of life, which are used to obtain quality-adjusted life years in pharmacoeconomic evaluations. A short-term utility improvement has been recently reported after hepatitis C viral clearance, although scarce data exists regarding the long-term variation of these parameters.PurposeTo assess the change in health utility values for patients cured of hepatitis C virus infection, one year after successful treatment with direct-acting antivirals, and the variables associated to that change.Material and methodsObservational, prospective study included cured patients with oral direct-acting antivirals between May 2016 and April 2017. The EQ-5D-5L questionnaire was used to obtain utilities, previous therapy and one year after its end (post48). Differences in the utility medians were compared using the Wilcoxon test. The percentage of disutility reduction was obtained as (post48 – baseline)/(1-baseline)×100. Multivariable linear regression analysis was carried out, adjusting by sex, age, HIV co-infection, baseline limitation of mobility, anxiety-depression and degree of liver fibrosis before treatment. Outcome variable was the difference post48 – baseline utility value.ResultsOne hundred and ninety-nine patients were enrolled, 65% male. Cirrhosis was present in 29% of the patients and HIV co-infection in 32%. Globally, median health utilities increased from 0.857 at baseline to 0.932 at post-48 (+0.075, p&lt;0.001). In HIV co-infected patients, utilities increased from 0.871 to 0.932 at post 48 (+0.061, p=0.001) and in cirrhotic patients from 0.809 to 0.890 (+0.081, p&lt;0.001). This improvement supposed a whole reduction in disutility of 52%: 47% in HIV co-infected and 42% in cirrhotic patients. In multivariate analysis, moderate-advanced fibrosis (F2–F3) and cirrhosis were associated with higher utility improvement than those with lower fibrosis degree (β=0.06; 95% CI, 0.001 to 0.12 and β=0.07; 95% CI, 0.003 to 0.13, respectively).ConclusionA long-term improvement in health utilities occurs in chronic hepatitis C patients successfully treated with direct-acting antivirals, even in HCV/HIV co-infected. This benefit is especially evident in patients with advanced fibrosis. The availability of utility values obtained directly from treated patients contributes to future economic evaluations of these new drugs.References and/or acknowledgementsEIPT-VHC project funded by the Spanish Ministry of Health and Carlos III Institute of Health.Conflict of interestCorporate-sponsored research or other substantive relationships:Regina Juanbeltz has received funding from the Carlos III Institute of Health with the European Regional Development Fund (CM17/00095).</description><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Infections</subject><subject>Liver cirrhosis</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kM1KAzEUhQdRsGjfIeA6NT_TZLKUom2h4MLuQyZzx0mZzoxJRulCcOOL-iSm1Lq6h3MP53K_LEOUzCjl4h52zdAYv8eMUIXBNIPtu3pGL7IJI7nESon88l_PxXU2DcGVZM55oXKuJtknXb8sMSH05-t7BaaNDRqja110EJDrkG183zmLGhhMTG5AC3RU0MWA-g7QAYxHpo7gURithRDqsUXRg4n7FEIfLlVWzoON2NjouldkuujenTdtuM2u6jRg-jdvsu3T43axwpvn5XrxsMElZYxiKIgwquKgpMwtiAJkCRXkdVFxKUvDGEirGJS0ymVVMZM8mfac1lTYOb_J7k61g-_fRghR7_rRd-miZlSl50khRErxU6rc7_Tg3d74g6ZEH0nrM2l9JK3PpDXlvwCzejU</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Juanbeltz, R</creator><creator>Goñi-Esarte, S</creator><creator>Martínez-Baz, I</creator><creator>San Miguel, R</creator><creator>Zozaya, JM</creator><creator>Rivero, M</creator><creator>Herrero, I</creator><creator>Larrayoz, B</creator><creator>Sarobe, M</creator><creator>Castilla, J</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201903</creationdate><title>1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals</title><author>Juanbeltz, R ; Goñi-Esarte, S ; Martínez-Baz, I ; San Miguel, R ; Zozaya, JM ; Rivero, M ; Herrero, I ; Larrayoz, B ; Sarobe, M ; Castilla, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1221-e806a9d3e9774ce68e7bede4f8d377ba22e7c92eb1d47dd2a7ba7de431f16c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Infections</topic><topic>Liver cirrhosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Juanbeltz, R</creatorcontrib><creatorcontrib>Goñi-Esarte, S</creatorcontrib><creatorcontrib>Martínez-Baz, I</creatorcontrib><creatorcontrib>San Miguel, R</creatorcontrib><creatorcontrib>Zozaya, JM</creatorcontrib><creatorcontrib>Rivero, M</creatorcontrib><creatorcontrib>Herrero, I</creatorcontrib><creatorcontrib>Larrayoz, B</creatorcontrib><creatorcontrib>Sarobe, M</creatorcontrib><creatorcontrib>Castilla, J</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juanbeltz, R</au><au>Goñi-Esarte, S</au><au>Martínez-Baz, I</au><au>San Miguel, R</au><au>Zozaya, JM</au><au>Rivero, M</au><au>Herrero, I</au><au>Larrayoz, B</au><au>Sarobe, M</au><au>Castilla, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2019-03</date><risdate>2019</risdate><volume>26</volume><issue>Suppl 1</issue><spage>A1</spage><epage>A1</epage><pages>A1-A1</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundHealth utilities are measures of quality of life, which are used to obtain quality-adjusted life years in pharmacoeconomic evaluations. A short-term utility improvement has been recently reported after hepatitis C viral clearance, although scarce data exists regarding the long-term variation of these parameters.PurposeTo assess the change in health utility values for patients cured of hepatitis C virus infection, one year after successful treatment with direct-acting antivirals, and the variables associated to that change.Material and methodsObservational, prospective study included cured patients with oral direct-acting antivirals between May 2016 and April 2017. The EQ-5D-5L questionnaire was used to obtain utilities, previous therapy and one year after its end (post48). Differences in the utility medians were compared using the Wilcoxon test. The percentage of disutility reduction was obtained as (post48 – baseline)/(1-baseline)×100. Multivariable linear regression analysis was carried out, adjusting by sex, age, HIV co-infection, baseline limitation of mobility, anxiety-depression and degree of liver fibrosis before treatment. Outcome variable was the difference post48 – baseline utility value.ResultsOne hundred and ninety-nine patients were enrolled, 65% male. Cirrhosis was present in 29% of the patients and HIV co-infection in 32%. Globally, median health utilities increased from 0.857 at baseline to 0.932 at post-48 (+0.075, p&lt;0.001). In HIV co-infected patients, utilities increased from 0.871 to 0.932 at post 48 (+0.061, p=0.001) and in cirrhotic patients from 0.809 to 0.890 (+0.081, p&lt;0.001). This improvement supposed a whole reduction in disutility of 52%: 47% in HIV co-infected and 42% in cirrhotic patients. In multivariate analysis, moderate-advanced fibrosis (F2–F3) and cirrhosis were associated with higher utility improvement than those with lower fibrosis degree (β=0.06; 95% CI, 0.001 to 0.12 and β=0.07; 95% CI, 0.003 to 0.13, respectively).ConclusionA long-term improvement in health utilities occurs in chronic hepatitis C patients successfully treated with direct-acting antivirals, even in HCV/HIV co-infected. This benefit is especially evident in patients with advanced fibrosis. The availability of utility values obtained directly from treated patients contributes to future economic evaluations of these new drugs.References and/or acknowledgementsEIPT-VHC project funded by the Spanish Ministry of Health and Carlos III Institute of Health.Conflict of interestCorporate-sponsored research or other substantive relationships:Regina Juanbeltz has received funding from the Carlos III Institute of Health with the European Regional Development Fund (CM17/00095).</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2019-eahpconf.1</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A1-A1
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2190010866
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Hepatitis
Hepatitis C
Infections
Liver cirrhosis
title 1ISG-001 Health utilities in chronic hepatitis C patients one year after successful treatment with direct-acting antivirals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A49%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1ISG-001%E2%80%85Health%20utilities%20in%20chronic%20hepatitis%20C%20patients%20one%20year%20after%20successful%20treatment%20with%20direct-acting%20antivirals&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Juanbeltz,%20R&rft.date=2019-03&rft.volume=26&rft.issue=Suppl%201&rft.spage=A1&rft.epage=A1&rft.pages=A1-A1&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-eahpconf.1&rft_dat=%3Cproquest_bmj_p%3E2190010866%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190010866&rft_id=info:pmid/&rfr_iscdi=true